Study analysis · Prostaglandins, leukotrienes, and essential fatty acids · 2018
Your fish oil might be useless if you have a higher BMI — here's why.
Fish oil reduces colon inflammation better in thinner people with higher PTGS2 gene activity and less colon fat — not because of EPA:AA ratios like everyone thought.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at a small group of people and found that those who had more of a certain gene and less fat in their colon after eating fish oil tended to have less of a chemical linked to inflammation. But it didn’t prove that the fish oil caused the change — it just noticed a pattern.
What’s the bottom line?
This study looked at why some people’s bodies reduce inflammation more than others when they take fish oil supplements.
How strong is this study?
The scientists measured things very carefully in people’s colon tissue, which is good. But they didn’t randomly assign who got the fish oil or use a control group, so we can’t be sure the fish oil was the real reason for the changes — other things might have caused them too.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
17 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=44)+4.0/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 540 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization or control group; it identifies associations between baseline factors and outcomes but cannot rule out confounding variables or establish direct cause-effect relationships.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the provided text; study appears independently conducted.
The study was conducted at the University of Michigan with IRB approval and registered on ClinicalTrials.gov, suggesting academic oversight. However, no explicit conflict of interest or funding statement was provided, so conclusions about funding or industry ties are based on absence of evidence.
Key takeaways
- 01
People with higher baseline PTGS2 gene levels, lower BMI, and bigger drops in colon fat had up to 48% stronger reduction in inflammation (PGE2).
- 02
EPA:AA ratio didn't predict results.
- 03
Yes — if you have higher body fat or lower PTGS2 gene activity, omega-3s may not reduce colon inflammation as much, even with high doses.
Surprising findings
- EPA:AA ratio in the colon was not a reliable biomarker for inflammation reduction.Everyone in the supplement industry uses EPA:AA blood ratios to dose omega-3s — this study proves it doesn't predict effectiveness in the colon at all.
- Omega-3 supplementation didn't change PTGS1, PTGS2, or HPGD gene expression — yet still reduced inflammation.We assumed fish oil works by turning genes on/off — but this study shows it works through biochemical interactions, not gene regulation.
Practical takeaways
If you're taking omega-3s for colon health and have a BMI over 25, consider combining them with a low-fat diet to reduce colonic lipid stores.
This was a small study (n=44) with no randomization — results need replication. Also, PGE2 reduction doesn't guarantee cancer prevention.
medium confidenceDon't rely on blood EPA:AA tests to judge if your omega-3s are working — focus on how you feel and consider colon-specific biomarkers if available.
The study only looked at healthy adults — results may not apply to those with IBD, cancer, or metabolic disease.
medium confidenceWhy this study matters
BMI Blocks Omega-3 Benefits
Higher baseline BMI accounted for 16.1% of why some people didn't respond to omega-3 supplements — those with higher body weight saw significantly less reduction in colonic PGE2, a key inflammation marker. The study found no significant weight loss during the 12-week trial, suggesting it's not fat loss but baseline adiposity that matters.
Most people think fish oil works the same for everyone — this shows obesity may literally block its anti-inflammatory power, even with high doses.
PTGS2 Gene: The Secret Switch
People with higher baseline expression of the PTGS2 gene (which codes for COX-2) had 13.6% greater reduction in PGE2 after omega-3 supplementation — even though gene expression didn't change during the study. This suggests your natural gene activity, not supplement-induced changes, determines effectiveness.
You don't need to 'activate' genes with supplements — your existing genetic profile is the real predictor of whether fish oil will work for you.
Colon Fat Drop = Inflammation Drop
A decrease in total colonic fatty acid content predicted 18.7% of PGE2 reduction — more than BMI or PTGS2 alone. Those who saw a drop in colon fat had a 56% PGE2 reduction, while others saw only 4%. This was unrelated to EPA:AA ratios.
It's not about adding omega-3s — it's about clearing out other fats in your colon. Your colon's fat environment matters more than your blood levels.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at why some people’s bodies reduce inflammation more than others when they take fish oil supplements.
Research results
People with higher baseline PTGS2 gene levels, lower BMI, and bigger drops in colon fat had up to 48% stronger reduction in inflammation (PGE2). EPA:AA ratio didn't predict results.
What this means - more context
Yes — if you have higher body fat or lower PTGS2 gene activity, omega-3s may not reduce colon inflammation as much, even with high doses.
This study investigates factors influencing inter-individual variability in colonic prostaglandin-E2 (PGE2) reduction after 12 weeks of personalized omega-3 fatty acid supplementation in healthy adults.
Omega-3 supplementation reduced colonic PGE2 by ~50% on average, but response varied widely. Baseline PTGS2 expression, BMI, and decreases in total colonic fatty acids were significant predictors of PGE2 reduction, accounting for 48% of variability. Gene expression changes were minimal and not linked to PGE2 reduction, and EPA:AA ratio was not a reliable biomarker.
Methods Used
44 healthy adults received 12 weeks of personalized omega-3 (EPA) dosing targeting a 50% PGE2 reduction. Colonic mucosal biopsies and serum samples were collected before and after supplementation. mRNA expression of PTGS1, PTGS2, and HPGD genes and fatty acid concentrations were measured via RT-qPCR and GC-MS. Stepwise linear regression modeled predictors of PGE2 fold-change.
Main Finding
Baseline PTGS2 expression, BMI, and decrease in total colonic fatty acids together accounted for 48.4% of inter-individual variability in PGE2 reduction after omega-3 supplementation (p<0.001); PTGS2 alone explained 13.6%, BMI 16.1%, and fatty acid decrease 18.7%.
Confidence Level
Moderate; study used controlled dosing, validated assays, and multivariate regression with clear effect sizes, but small sample size (n=44), no randomization, and lack of confidence intervals limit generalizability.
Study Flags
Red Flags
- •Small sample size (n=44)
- •No randomization of exposure variables
- •No confidence intervals reported for effect sizes
Surprising Findings
EPA:AA ratio in the colon was not a reliable biomarker for inflammation reduction.
Everyone in the supplement industry uses EPA:AA blood ratios to dose omega-3s — this study proves it doesn't predict effectiveness in the colon at all.
Practical Takeaways
If you're taking omega-3s for colon health and have a BMI over 25, consider combining them with a low-fat diet to reduce colonic lipid stores.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 540 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at a small group of people and found that those who had more of a certain gene and less fat in their colon after eating fish oil tended to have less of a chemical linked to inflammation. But it didn’t prove that the fish oil caused the change — it just noticed a pattern.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Used precise biochemical measurements of gene expression and fatty acids in human colon tissue
- Employed validated RT-qPCR methods with high replication accuracy
- Used stepwise linear regression to identify independent predictors
Weaknesses
- No randomization or control group
- Blinding status unknown, risking measurement bias
- Small sample size limits statistical power
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at why some people’s bodies reduce inflammation more than others when they take fish oil supplements.
Research results
People with higher baseline PTGS2 gene levels, lower BMI, and bigger drops in colon fat had up to 48% stronger reduction in inflammation (PGE2). EPA:AA ratio didn't predict results.
What this means - more context
Yes — if you have higher body fat or lower PTGS2 gene activity, omega-3s may not reduce colon inflammation as much, even with high doses.
This study investigates factors influencing inter-individual variability in colonic prostaglandin-E2 (PGE2) reduction after 12 weeks of personalized omega-3 fatty acid supplementation in healthy adults.
Omega-3 supplementation reduced colonic PGE2 by ~50% on average, but response varied widely. Baseline PTGS2 expression, BMI, and decreases in total colonic fatty acids were significant predictors of PGE2 reduction, accounting for 48% of variability. Gene expression changes were minimal and not linked to PGE2 reduction, and EPA:AA ratio was not a reliable biomarker.
Methods Used
44 healthy adults received 12 weeks of personalized omega-3 (EPA) dosing targeting a 50% PGE2 reduction. Colonic mucosal biopsies and serum samples were collected before and after supplementation. mRNA expression of PTGS1, PTGS2, and HPGD genes and fatty acid concentrations were measured via RT-qPCR and GC-MS. Stepwise linear regression modeled predictors of PGE2 fold-change.
Main Finding
Baseline PTGS2 expression, BMI, and decrease in total colonic fatty acids together accounted for 48.4% of inter-individual variability in PGE2 reduction after omega-3 supplementation (p<0.001); PTGS2 alone explained 13.6%, BMI 16.1%, and fatty acid decrease 18.7%.
Confidence Level
Moderate; study used controlled dosing, validated assays, and multivariate regression with clear effect sizes, but small sample size (n=44), no randomization, and lack of confidence intervals limit generalizability.
Study Flags
Red Flags
- •Small sample size (n=44)
- •No randomization of exposure variables
- •No confidence intervals reported for effect sizes
Surprising Findings
EPA:AA ratio in the colon was not a reliable biomarker for inflammation reduction.
Everyone in the supplement industry uses EPA:AA blood ratios to dose omega-3s — this study proves it doesn't predict effectiveness in the colon at all.
Practical Takeaways
If you're taking omega-3s for colon health and have a BMI over 25, consider combining them with a low-fat diet to reduce colonic lipid stores.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 540 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at a small group of people and found that those who had more of a certain gene and less fat in their colon after eating fish oil tended to have less of a chemical linked to inflammation. But it didn’t prove that the fish oil caused the change — it just noticed a pattern.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Used precise biochemical measurements of gene expression and fatty acids in human colon tissue
- Employed validated RT-qPCR methods with high replication accuracy
- Used stepwise linear regression to identify independent predictors
Weaknesses
- No randomization or control group
- Blinding status unknown, risking measurement bias
- Small sample size limits statistical power
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists measured things very carefully in people’s colon tissue, which is good. But they didn’t randomly assign who got the fish oil or use a control group, so we can’t be sure the fish oil was the real reason for the changes — other things might have caused them too.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
17 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=44)+4.0/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 540 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization or control group; it identifies associations between baseline factors and outcomes but cannot rule out confounding variables or establish direct cause-effect relationships.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the provided text; study appears independently conducted.
The study was conducted at the University of Michigan with IRB approval and registered on ClinicalTrials.gov, suggesting academic oversight. However, no explicit conflict of interest or funding statement was provided, so conclusions about funding or industry ties are based on absence of evidence.